KOENNINGS STEPHANIE,CHATTERJI ASHISH,HUANG JINGJUN,SANDHU HARPREET K.,SHAH NAVNIT HARGOVINDAS,LINDENSTRUTH KAI
申请号：
NZ60542411
公开号：
NZ605424A
申请日:
2011.08.08
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed are pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists for example 2-CHLORO-4-[1-(4-FLUORO-PHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHYNYL]-PYRIDINE or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with a rate-controlling polymer and a pH responding polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent release profile with NMT 70 % in one hour, NMT 85 % in 4 hour, and NLT 80 % in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment- Resistant Depression (TRD) and Fragile X Syndrome.
